These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 9313749)

  • 1. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
    Rachman J; Levy JC; Barrow BA; Manley SE; Turner RC
    Diabetes; 1997 Oct; 46(10):1557-62. PubMed ID: 9313749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
    Rachman J; Payne MJ; Levy JC; Barrow BA; Holman RR; Turner RC
    Diabetes Care; 1998 May; 21(5):810-6. PubMed ID: 9589246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea.
    Dworacka M; Abramczyk M; Winiarska H; Kuczynski S; Borowska M; Szczawinska K
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):14-21. PubMed ID: 16425966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus.
    Prigeon RL; Jacobson RK; Porte D; Kahn SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3295-8. PubMed ID: 8784086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes.
    Inoguchi T; Umeda F; Kakimoto M; Sako Y; Ishii H; Noda K; Kunisaki M; Imamura M; Yu HY; Etoh T; Yoshikawa H; Aoki T; Hashimoto T; Nawata H
    Endocr J; 2000 Dec; 47(6):763-70. PubMed ID: 11228051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
    Karunakaran S; Hammersley MS; Morris RJ; Turner RC; Holman RR
    Metabolism; 1997 Dec; 46(12 Suppl 1):56-60. PubMed ID: 9439561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperproinsulinemia is not a characteristic feature in the offspring of patients with different phenotypes of type II diabetes.
    Vauhkonen IK; Niskanen LK; Mykkänen L; Haffner SM; Uusitupa MI; Laakso M
    Eur J Endocrinol; 2000 Aug; 143(2):251-60. PubMed ID: 10913945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of gliclazide on plasma insulin, intact and 32/33 split proinsulin in South Asian subjects with Type 2 diabetes mellitus.
    Ammari F; Davies MJ; Koppiker N; Gregory R; Burden AC
    Diabet Med; 1999 Feb; 16(2):142-6. PubMed ID: 10229308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
    Matthews DR; Boland O
    Metabolism; 1997 Dec; 46(12 Suppl 1):5-9. PubMed ID: 9439551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
    Inoue I; Takahashi K; Noji S; Awata T; Negishi K; Katayama S
    Diabetes Res Clin Pract; 1997 Jun; 36(3):143-51. PubMed ID: 9237780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related alteration of pancreatic beta-cell function. Increased proinsulin and proinsulin-to-insulin molar ratio in elderly, but not in obese, subjects without glucose intolerance.
    Shimizu M; Kawazu S; Tomono S; Ohno T; Utsugi T; Kato N; Ishi C; Ito Y; Murata K
    Diabetes Care; 1996 Jan; 19(1):8-11. PubMed ID: 8720525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proinsulin immunoreactivity in identical twins discordant for noninsulin-dependent diabetes mellitus.
    Røder ME; Vaag A; Hartling SG; Dinesen B; Lanng S; Beck-Nielsen H; Binder C
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2359-63. PubMed ID: 7629230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.
    Røder ME; Porte D; Schwartz RS; Kahn SE
    J Clin Endocrinol Metab; 1998 Feb; 83(2):604-8. PubMed ID: 9467581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance.
    Reaven GM; Chen YD; Hollenbeck CB; Sheu WH; Ostrega D; Polonsky KS
    J Clin Endocrinol Metab; 1993 Jan; 76(1):44-8. PubMed ID: 8421101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
    Chazan AC; Gomes MB
    Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parallel changes of proinsulin and islet amyloid polypeptide in glucose intolerance.
    MacNamara CM; Barrow BA; Manley SE; Levy JC; Clark A; Turner RC
    Diabetes Res Clin Pract; 2000 Oct; 50(2):117-26. PubMed ID: 10960722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of conventional and intensified insulin therapy on free-insulin profiles and glycemic control in NIDDM.
    Lindström TH; Arnqvist HJ; von Schenck HH
    Diabetes Care; 1992 Jan; 15(1):27-34. PubMed ID: 1737539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.